|
Directors
Jeremy Poole – Chairman
A Biological Scientist and graduate of Manchester Business School with over 40 years multifunctional experience in the Pharmaceutical Industry. In 2004 Jeremy retired from the board of AAH Pharmaceuticals Ltd, the leading distributor and has since been active in consultancy and interim management. Prior to this he held board level positions in both the research based (Fisons Pharmaceuticals) and generic sectors (CP Pharmaceuticals).
William Beresford - Technical Director
An industrial pharmacist with more than 30 years of experience in development and regulatory affairs and is responsible for all Technical and Regulatory issues. Past senior management experience includes Smith Kline & French, Nicholas, Fisons and CP Pharmaceuticals. William is the author of over 50 Chemistry & Pharmacy Expert Reports and is a Qualified Person under the requirements of the Medicines Act and EC Directive 75/319.
Paul Boulton - Finance Director
A qualified accountant, graduating from the London School of Economics, Paul has Board level experience in a number of industries and is responsible for all financial, administration and legal matters . Past experience includes Pilkington Brothers, Ciba-Geigy (now Novartis) and March Group Plc.
Brian Dickson – Non-Executive / Medical Director
A physician with more than 20 years experience in development at major pharmaceutical and biotech companies. Also Chief Medical Officer of Cornerstone Therapeutics Inc., Dr. Dickson is responsible for developing new products in order to obtain timely regulatory approval, assisting in attaining new products for the company, designing and managing all clinical studies.
Dr. Dickson worked in senior management with Smith, Kline & French Laboratories Ltd., Searle and Warner Lambert / Parke Davis. Further, he was Chief Medical Officer at the contract research organization Inveresk Ltd. (Charles River Laboratories). Dr. Dickson has led teams that have obtained 18 FDA approvals and has presented at 14 FDA Advisory Boards.
In addition to Dr. Dickson’s industry experience, he was a past Editor-in-Chief of the Journal of Pharmaceutical Medicine and is a member of the Faculty of Pharmaceutical Medicine. Dr. Dickson also served as a subcommittee member for nutrition and anemia at the World Health Organization. Dr. Dickson received his Doctor of Medicine from Adelaide University in South Australia.
Julian Viggers – Non-Executive
Head of Technology Investment and leads the seed and early stage technology investment team at Enterprise Ventures.
Julian joined EV in 2004 and has over eight years' venture capital experience, having worked as an Adviser on the corporate finance side, and as Principal in traditional private equity deals and early stage technology and emerging healthcare sectors.
Prior to joining EV, Julian was a Director at AIM-listed healthcare and IT investor BioProjects. His role included structuring and monitoring of new investments, and liason with both the scientific community and investors. He was responsible for BioProjects' most successful investments, Acolyte Biomedica and Vialogy. Julian oversaw as an Non Executive Director, both the sale of Acolyte Biomedica and BioProjects' successful reverse merger with lead investment, Vialogy, now an AIM company valued at £28m.
Prior to BioProjects, he was an Associate Partner at London Accountants, NCL Smith and Williamson, where he focused on the private equity markets, and spent eighteen months on secondment with Barclays Ventures. Julian is a Chartered Accountant and holds a degree in Geology with Chemistry from the University of Southampton.
|
